A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13
Supplementary Table 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Unknown|2023Cited by 0
Data from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Unknown|2023Cited by 0
Supplementary Table 2 from A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Unknown|2023Cited by 0